Economics of antibiotic administration

Critical Care Nursing Clinics of North America

Volumn 15, Issue 1, 2003, Pages 89-96

  Sommers, Ben ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Tosteson Medical Education Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFOXITIN; CEFTIZOXIME; GENTAMICIN; METRONIDAZOLE; MEZLOCILLIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; NEWBORN SEPSIS; PNEUMONIA; REVIEW; COST BENEFIT ANALYSIS; DECISION MAKING; DRUG RESISTANCE; ECONOMICS; UNITED STATES;

ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; DECISION MAKING; DRUG COSTS; DRUG RESISTANCE; HEALTH POLICY; HUMANS; UNITED STATES;

EID: 2342523370     PISSN: 08995885     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0899-5885(02)00029-1     Document Type: Review

References (12)

1. Nordenberg T. Miracle drugs vs. superbugs. FDA Consumer Magazine. 32(6):Nov/ Dec 1998;22-25
2. PhRMA 2001 Industry Profile. Detailed results from the PhRMA annual survey. Washington, D.C.: Pharmaceutical Research and Manufacturers of America (PhRMA); p. 115-42
3. Zeckhauser R. Medical insurance: a case study of the trade-off between risk spreading and appropriate incentives. Journal of Economic Theory. 2:1970;10-26
4. Weinstein M.C., Read J.L., MacKay D.N., et al. Cost-effective choice of antimicrobial therapy for serious infections. J Gen Intern Med. 1:1986;351-363
5. Hammitt J.K. Valuing mortality risk: theory and practice. Environ Sci Technol. 34(8):2000;1396-1400
6. Thureen P.J., Reiter P.D., Gresores A., et al. Once- versus twice-daily gentamicin dosing in neonates >34 week's gestation: cost-effectiveness analyses. Pediatrics. 103(3):1999;594-598
7. Cohen F.L., Tartasky D. Microbial resistance to drug therapy: a review. Am J Infect Control. 25(1):1997;51-64
8. Kaiser Commission on Medicaid and the Uninsured The uninsured and their access to health care. Available at: www.kff.org/content/2000/1420 2000;. Accessed October 31, 2002
9. Centers for Disease Control Background on antibiotic resistance. Promoting appropriate antibiotic use in the community. Available at: www.cdc.gov/drugresistance/community/ background:2001;. Accessed October 31, 2002
10. Lieberman P.B., Wootan M.G. Protecting the crown jewels of medicine: a strategic plan to reduce the spread of antibiotic resistance. 1998;Center for Science in the Public Interest, Washington DC
11. Stuart B., Zacker C. Who bears the burden of Medicaid drug copayment policies? Health Aff (Millwood). 18(2):1999;201-212
12. Johnson J.A., Friesen E. Reassessing the relevance of pharmacoeconomic analyses in formulary decisions. Pharmacoeconomics. 13:1998;479-485